Sumitomo Mitsui DS Asset Management Company Ltd Has $21.54 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,994 shares of the pharmaceutical company’s stock after purchasing an additional 6,904 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Vertex Pharmaceuticals were worth $21,538,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VRTX. Costello Asset Management INC boosted its position in Vertex Pharmaceuticals by 3.6% in the second quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock valued at $307,000 after buying an additional 24 shares in the last quarter. Kovack Advisors Inc. lifted its stake in shares of Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares during the last quarter. Newman Dignan & Sheerar Inc. lifted its stake in shares of Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after acquiring an additional 25 shares during the last quarter. Eastern Bank boosted its holdings in shares of Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Eastern Bank now owns 1,635 shares of the pharmaceutical company’s stock valued at $728,000 after acquiring an additional 25 shares in the last quarter. Finally, Washington Trust Advisors Inc. grew its position in Vertex Pharmaceuticals by 8.4% during the 2nd quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company’s stock worth $144,000 after acquiring an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $463.86 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The firm’s fifty day moving average is $443.50 and its 200-day moving average is $427.33. The firm has a market cap of $117.69 billion, a P/E ratio of 32.71 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the business earned $4.38 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VRTX. Barclays lifted their price target on Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 4th. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price objective for the company in a report on Tuesday. Leerink Partners lifted their target price on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research report on Monday, December 29th. Morgan Stanley set a $564.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, December 5th. Finally, UBS Group began coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $535.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $503.80.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported progress advancing suzetrigine into a Phase‑3 trial for diabetic nerve pain — a meaningful new indication that could broaden revenue beyond its cystic fibrosis franchise. Vertex Advances Suzetrigine Phase 3 Trial
• Positive Sentiment: Wolfe Research upgraded the stock recently, and several sell‑side firms have raised price targets (e.g., Leerink, Wells Fargo), supporting upside expectations and a consensus target near ~$504. Vertex Stock Rating Upgraded by Wolfe Research
• Neutral Sentiment: Market recaps note short‑term price weakness even as fundamentals and analyst coverage remain constructive — context for volatile daily moves but not necessarily a change to the longer‑term thesis. Vertex Stock Dips While Market Gains: Key Facts
• Neutral Sentiment: Another market note highlighted the recent down‑day versus a broader market uptick — useful color for traders but not new company‑specific catalysts. Vertex Stock Falls Amid Market Uptick
• Negative Sentiment: Two senior executives disclosed sizable open‑market sales this week — EVP Charles Wagner Jr. sold 9,532 shares (~$4.4M at ~$461/share) and EVP Ourania Tatsis sold 4,500 shares (~$2.14M at ~$475/share). Large insider sales can pressure sentiment even if not tied to company fundamentals. Charles Wagner, Jr. Sells 9,532 Shares
• Negative Sentiment: Separate filing shows EVP Ourania Tatsis’ 4,500‑share sale and a near‑10% reduction in her position — another factor likely weighing on intraday selling pressure. Ourania Tatsis Insider Sale
• Negative Sentiment: A Seeking Alpha piece and some sell‑side notes discuss the near‑term cost and execution risk of expanding beyond cystic fibrosis, which can temper investor appetite until new indications (like suzetrigine) de‑risk. The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)

Insider Activity

In related news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the sale, the executive vice president owned 37,725 shares in the company, valued at $17,202,600. This represents a 27.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the completion of the sale, the executive vice president owned 42,293 shares of the company’s stock, valued at approximately $20,088,752.07. The trade was a 9.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 165,105 shares of company stock valued at $73,858,523 in the last ninety days. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.